Aeon Expects Imminent Data On Botox Biosimilar

Structure Analysis Slated To Complete In Q3 Ahead Of Q4 FDA Meeting

 
• By Dave Wallace
  
Aeon is developing a Botox biosimilar (Shutterstock)

More from Biosimilars

More from Products